Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies
Kanellopoulos, Alexandros McIlroy, Graham Paneesha, Shankara Kaparou, Maria Kishore, Bhuvan Lovell, Richard Elmoamly, Shereef Davies, David Xenou, Evgenia Horgan, Claire
Kanellopoulos, Alexandros
McIlroy, Graham
Paneesha, Shankara
Kaparou, Maria
Kishore, Bhuvan
Lovell, Richard
Elmoamly, Shereef
Davies, David
Xenou, Evgenia
Horgan, Claire
Citations
Altmetric:
Affiliation
Heart of England NHS Foundation Trust; University of Birmingham; South Warwickshire University NHS Foundation Trust
Other Contributors
Publication date
2018-11-19
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
This European Society for Blood and Marrow Transplantation conference abstract reports that three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab based allogeneic stem cell transplants for haematological malignancies.
Citation
Kanellopoulos A, McIlroy G, Elmoamly DD, Xenou E, Horgan C, Kinsella F, Arbuthnot C, Borg A, Randall K, Ryann L, Collins K. Three-month mixed T-cell chimerism followed by donor lymphocyte infusions is associated with superior outcomes in reduced-intensity alemtuzumab-based allogeneic stem cell transplants for haematological malignancies. Bone Marrow Transplantation. 2018;53:295. doi: 10.1038/s41409-018-0354-7.
Type
Conference Output